TIGIT / VSTM3 Protein (His Tag)

T cell immunoreceptor with Ig and ITIM domains Protein

TIGIT/VSTM3 Price Information

50ug: Inquiring Price; 200ug: Inquiring Price; ≥1mg Bulk:  Inquiring Price

TIGIT/VSTM3 Protein Product Information

• Synonym: DKFZp667A205, FLJ39873, VSIG9, VSTM3, WUCAM,TIGIT
• Protein Construction: A DNA sequence encoding the extracellular domain of human TIGIT (NP_776160.2) ( Met 1-Phe 138 ) with a C-terminal polyhistidine tag was expressed.
• Source: Human
• Expression Host: Human Cells

TIGIT/VSTM3 Protein QC Testing

• Purity: >95% as determined by SDS-PAGE.
• Endotoxin: < 1.0 EU per 1μg of the protein as determined by the LAL method.
• Stability: Samples are stable for up to twelve months from date of receipt at -70℃
• Predicted N terminal: Cys 24
• Molecular Mass: The secreted recombinant human TIGIT comprises 128 amino acids with a predicted molecular mass of 14.2 kDa. As a result of glycosylation, the apparent molecular mass of rhTIGIT is approximately 20-22 kDa in non-reduced SDS-PAGE.
• Formulation: Lyophilized from sterile PBS, pH7.4
• SDS-PAGE:

TIGIT/VSTM3 Protein Usage Guide

• Storage: Store it under sterile conditions at -70℃. It is recommended that the protein be aliquoted and be used as soon as possible. Avoid repeated freeze-thaw cycles.
• Reconstitution: A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.

TIGIT/VSTM3 Protein Description

TIGIT, also known as V-set and transmembrane domain-containing protein 3 (VSTM3) or V-set and immunoglobulin domain-containing protein 9 (VSIG9) is a new surface protein containing an immunoglobulin variable domain, a transmembrane domain and an immunoreceptor tyrosine-based inhibitory motif (ITIM). TIGIT is expressed on regulatory, memory, activated T cells and NK cells. It binds PVR with high affinity, and PVRL2 with lower affinity, but not PVRL3. Knockdown of TIGIT with siRNA in human memory T cells did not affect T cell responses, however, TIGIT inhibits NK cytotoxicity directly through its ITIM. TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. The binding of PVR to TIGIT on human dendritic cells enhanced the production of IL-10 and diminished the production of IL-12p40. In addition, TIGIT counter inhibits the NK-mediated killing of tumor cells and protects normal cells from NK-mediated cytotoxicity thus providing an “alternative self” mechanism for MHC class I inhibition.

References

1. Yu, X. et al., 2009, Nat Immunol. 10(1): 48-57.

2. Stanietsky, N. et al., 2009, Proc Natl Acad Sci. 106(42):17858-17863.